Cobimetinib and binimetinib were granted FDA approval also as combination therapy with BRAF inhibitors for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E/V600K mutation (Eroglu et al., 2016). This evidence concerns the gene BRAF and metastatic melanoma.